

Development and design of the BELpREG registration system for the collection of real-world data on medication use in pregnancy and mother-infant outcomes

1 **Laure Sillis**^{1,2}, **Veerle Foulon**¹, **Karel Allegaert**^{1,3,4,5}, **Annick Bogaerts**^{3,4,6}, **Maarten De Vos**^{3,7},
2 **Titia Hompes**^{8,9}, **Anne Smits**^{3,4,10}, **Kristel Van Calsteren**^{3,11}, **Jan Y Verbakel**^{12,13} and **Michael**
3 **Ceulemans**^{1,4,14*}

4 ¹Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU
5 Leuven, Leuven, Belgium

6 ²Research Foundation Flanders (FWO), Brussels, Belgium

7 ³Department of Development and Regeneration, KU Leuven, Leuven, Belgium

8 ⁴L-C&Y, Child and Youth Institute, KU Leuven, Leuven, Belgium

9 ⁵Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands

10 ⁶Faculty of Health, University of Plymouth, Devon, UK

11 ⁷Department of Electrical Engineering (ESAT), KU Leuven, Leuven, Belgium

12 ⁸Adult Psychiatry UPC, KU Leuven, Leuven, Belgium

13 ⁹Department of Neurosciences, KU Leuven, Leuven, Belgium

14 ¹⁰Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium

15 ¹¹Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium

16 ¹²Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

17 ¹³Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

18 ¹⁴Teratology Information Service, Pharmacovigilance Centre Lareb, 's Hertogenbosch, the Netherlands

19 * **Correspondence:** Michael Ceulemans (michael.ceulemans@kuleuven.be)

20 **Keywords: pregnancy; drug information; drug safety; pharmacovigilance;**
21 **pharmacoepidemiology; registry; observational research; Belgium.**

22

23 Abstract

24 Although medication use during pregnancy is common, most available products lack sufficient safety
25 information. As prospective data collection and perinatal pharmacoepidemiologic research on
26 medication safety in pregnancy did not exist in Belgium yet, the BELpREG data registration system
27 was developed. BELpREG enables comprehensive ‘real-world’ data collection on perinatal
28 medication use and mother-infant outcomes via online questionnaires that are completed by pregnant
29 women every four weeks during pregnancy and in the first eight weeks after childbirth. This paper
30 describes the development and current design of the BELpREG system, including the list of
31 BELpREG variables. To compile this list of variables, relevant documents were explored, followed
32 by consultation of an interdisciplinary expert panel. The included variables were structured in seven
33 categories: 1) Sociodemographic characteristics; 2) Information on the current pregnancy and health
34 status; 3) Maternal-obstetric history; 4) Use of medicines, folic acid / pregnancy vitamins and other
35 health products; 5) Substance use; 6) Pregnancy outcomes; and 7) Neonatal outcomes. An electronic
36 informed consent and linkage to medication databases, with images of drug packages and underlying
37 structured data fields, are built into the system. Data collection has officially started in November
38 2022. Based on its rigorous design, BELpREG holds the potential to be a successful and sustainable
39 research tool, enabling perinatal pharmacoepidemiologic research in Belgium and beyond.

40 1 Introduction

41 The use of medicines and health products in pregnancy occurs frequently (Lupattelli et al., 2014;
42 Gerbier et al., 2021; Ceulemans et al., 2022a; Gerbier et al., 2022). In Belgium, almost 90% of the
43 women use at least one medicine in pregnancy, excluding pregnancy vitamins (Larcin et al., 2021).
44 Safe use of medication in pregnancy is vital as the exposure to certain medicines may result in
45 adverse pregnancy, neonatal and/or infant outcomes. To date, there is a high need for reliable safety
46 information on perinatal medication use, also in Belgium (Ceulemans et al., 2020; Ceulemans et al.,
47 2022b). The Internet, including social media, is a commonly used source to search for safety
48 information (Sinclair et al., 2018), however, discrepancies have been found between online sources
49 (Nörby et al., 2021). Furthermore, social media posts often provide inaccurate information, affecting
50 women's perception and decisions about medication use (van Gelder et al., 2019).

51 Despite their frequent use, most available medicines lack sufficient safety information on their use
52 during pregnancy (Adam et al., 2011). On average, 27 years are needed to assign a precise risk
53 category to a medicine (Adam et al., 2011), and research to gain more information on the safe use of
54 medicines in pregnancy is challenging. Pregnant women are commonly excluded from clinical trials
55 assessing the efficacy and safety of new medicinal products (Shields and Lyerly, 2013; Scaffidi et al.,
56 2017; Zhao et al., 2022). As soon as a product is on the market, marketing authorisation holders
57 (MAHs) are involved in the continuous monitoring of medication safety in pregnancy via post-
58 marketing surveillance, including spontaneous reporting and (mandatory) product-specific pregnancy
59 registries. Still, a recent pan-European qualitative analysis performed by our team highlighted the
60 difficulties with respect to data collection on this topic MAHs suffer from, including underreporting,
61 the collection of incomplete information, and loss to follow-up (Sillis et al., 2022). A recent
62 landscape analysis also confirmed that only few post-marketing studies result in label updates (Roque
63 Pereira et al., 2022).

64 In addition to post-marketing surveillance, other data sources could be used to gain insight into
65 medication safety during pregnancy, as for example: population-based cohorts nested in health
66 utilisation databases (i.e., secondary use of health data) (Dandjinou et al., 2019; Huybrechts et al.,

67 2021; Moseholm et al., 2022), pregnancy registries held by non-MAHs (with or without a specific
68 focus on a pharmacotherapeutic class or therapeutic indication) (Hernandez-Diaz et al., 2012;
69 Chambers et al., 2019; Vorstenbosch et al., 2019), and data collection by Teratology Information
70 Services (Pauliat et al., 2021; Dao et al., 2022). Different data sources come with different strengths,
71 limitations, and methodological considerations (Hernandez-Diaz and Oberg, 2015; Huybrechts et al.,
72 2019; Panchaud et al., 2022). In 2019, the Innovative Medicines Initiative (IMI) project
73 ConcePTION was launched to create a sustainable ecosystem to generate and disseminate
74 information on medication safety in pregnancy and during breastfeeding. This goal also includes the
75 alignment of different organisations and approaches aimed at improving in the field of medication
76 safety for pregnant and breastfeeding women (ConcePTION, n.d.).

77 Unfortunately, in Belgium, pharmacoepidemiologic research on medication safety in pregnancy is
78 lacking. The required data for such research are neither routinely collected, nor easily accessible,
79 compared to other European countries with comprehensive data on birth cohorts (e.g., Norway, the
80 MoBa cohort) (Magnus et al., 2006) or with linked health utilisation databases (e.g., France,
81 EFEMERIS/POMME) (Lacroix et al., 2009; Benevent et al., 2019). This clearly highlights the need
82 for comprehensive data registration in Belgium, and initiatives to expand this research field.

83 In 2021, our interdisciplinary consortium received KU Leuven funding to develop, validate and
84 implement the BELpREG registration system in Belgium (“a **BEL**gian interdisciplinary initiative to
85 enhance **pregnancy related data REG**istration and research on medication use”). The BELpREG
86 registration system enables the collection of ‘real-world’, prospective, observational data on perinatal
87 medication use and mother-infant outcomes, by using online questionnaires to be completed by
88 pregnant women. BELpREG is a non-disease, indication, pharmacotherapeutic class or product-
89 specific registry. In BELpREG, medication exposure and outcome data of all pregnant women (≥ 18
90 years and receiving health care in Belgium) are collected. The obtained data will be used for
91 pharmacoepidemiologic research in Belgium and beyond. On the long-term, BELpREG aims to
92 contribute to the provision of evidence on medication safety to expecting parents and HCPs. Figure 1
93 shows a schematic overview of the BELpREG approach.

94 In this paper, we describe the development and current design of the BELpREG registration system,
95 including the list of BELpREG variables, and future possibilities. Hence, this overview will inform
96 (inter)national researchers, MAHs, regulators and policy organizations involved in medication safety
97 monitoring in pregnancy about the BELpREG initiative, germinating opportunities for international
98 data pooling, analysis and collaborative projects.

99 **Figure 1.** A schematic overview of the BELpREG approach.



101

102 **2 Materials and Methods**

103 **2.1 Timing of the Development of BELpREG**

104 The development of the BELpREG data registration system on perinatal medication use and mother-
105 infant outcomes occurred between March 2021 and October 2022.

106 **2.2 Development of the BELpREG Data Variables List**

107 To compile the list of variables for data collection in BELpREG, relevant documents were explored,
108 followed by a consultation of an interdisciplinary expert panel.

109 First, the list of Core Data Elements (CDE), which was recently compiled as part of the IMI
110 ConcePTION project (version December 2021, available via [https://www.imi-
111 conception.eu/results/deliverables/](https://www.imi-conception.eu/results/deliverables/)) was consulted. The CDE had previously been defined based on
112 in-depth discussions with experts in perinatal pharmacovigilance from in and outside the
113 pharmaceutical industry, resulting in a set of essential variables required for pregnancy
114 pharmacovigilance using prospective reports. The CDE aims to strengthen efficient collection of real-
115 world data on medication safety in pregnancy (ConcePTION, n.d.). Second, the CDE were
116 supplemented with variables defined in the European Medicines Agency (EMA) “Guideline on good
117 pharmacovigilance practices (GVP) - Product- or Population-Specific Considerations III: Pregnant
118 and breastfeeding women”. This document provides guidance to MAHs and competent authorities
119 with respect to data collection on pregnancy exposures and outcomes by listing questionnaire
120 elements (see Appendix 1 of the GVP guideline, version December 2019, available via
121 [https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-
122 pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf)). Finally,
123 additional input regarding the variables and response options was sought in questionnaires of existing
124 registration systems (i.e., Moeders van Morgen, The Netherlands; MotherToBaby, United States),
125 and from the centre of expertise in Belgium on alcohol and substance use (i.e., Flemish Expertise
126 Centre Alcohol and Other Drugs). These three approaches resulted in a preliminary set of variables,
127 which was the starting point for the expert consultation.

128 In a next step, an interdisciplinary expert panel was invited to contextualise the preliminary set of
129 variables to the Belgian setting by providing input with regard, but not limited, to the definition of
130 the variables, response options and formulations, and timing of the questions to be included in the
131 BELpREG questionnaires. The panel consisted of seven Belgian experts in the field of obstetrics,
132 neonatology/paediatrics (N = 2), midwifery, family medicine, perinatal psychiatry, and pharmacy,
133 and were consulted in two rounds. In the first round, the experts completed an online survey (in
134 Qualtrics; Augustus-September 2021) where they could indicate to which extent they agreed with
135 any variables and/or response options; additional suggestions could be provided via open text fields.
136 For each variable, experts were also asked to suggest the optimal timing and frequency of querying
137 this variable. In the second round, the survey results were discussed in group during a real-life
138 meeting, moderated by M.C. and L.S., to decide on inconsistent responses and/or any suggestions
139 raised (September 2021).

140

141 2.3 Development of the BELpREG Infrastructure

142 To develop the BELpREG registration system, including the technical infrastructure and legal,
143 privacy and ethical framework for data collection and management, collaboration with external
144 partners was set-up. Legal consultants with expertise in data protection and IP law in the field of life
145 sciences were involved, as well as the Data Protection Officer of our institute, solving questions
146 related to the collection of health data compliant with applicable privacy legislations, database
147 protection and the use of the collected data for research purposes. Besides, IT consultants with
148 extensive expertise in data systems related to medicines contributed to the construction of the
149 BELpREG registration system and facilitated the longitudinal framework for data collection and
150 linkage to existing databases (in collaboration with the IT department within our institute, KU
151 Leuven).

152 3 Results

153 3.1 BELpREG Data Categories and Variables

154 Overall, BELpREG encompasses questions on data variables categorized in one of the following
155 seven categories: 1) Sociodemographic characteristics; 2) Information on the current pregnancy and
156 health status; 3) Maternal-obstetric history; 4) Use of medicines, folic acid / pregnancy vitamins and
157 other health products; 5) Substance use; 6) Pregnancy outcomes; and 7) Neonatal outcomes (see
158 Table 1). Information on these categories will be longitudinally collected using questionnaires at
159 different time points during and after pregnancy. A detailed overview of the complete list of
160 BELpREG variables, per category, can be found in the Supplementary Material 1. To optimally
161 understand the remainder of this manuscript, some basic information about the categories is provided
162 in the following paragraphs.

163 1) The category *Sociodemographic characteristics* consists of basic identifiers of BELpREG
164 participants, as for example, zip code, nationality, ethnicity, or the socio-economic status of the
165 mother and biological father (the latter only if known).

166
167 2) *Information on the current pregnancy and health status* will provide details on the estimated
168 date of delivery (EDD), gestational age at completion of the pregnancy follow-up questionnaires,
169 plurality, pregnancy preparation/planning/follow-up, current and previous health status of mother and
170 biological father (e.g., comorbidities), and pregnancy complications diagnosed so far. Further, this
171 category includes a screening of depressive symptoms during pregnancy and the postnatal period
172 with the Edinburgh Depression Scale (EDS) (Cox et al., 1987; Bergink et al., 2011). The EDS is
173 considered the gold standard to detect PND (Cox et al., 1987). This scale was initially developed for
174 the postpartum period but has also been validated for assessment during pregnancy (Bergink et al.,
175 2011). It consists of a 10-item list regarding the severity of the depressive symptoms during the past
176 7 days.

177
178 3) The category *Maternal-obstetric history* includes details on previous pregnancies, including
179 miscarriages, elective terminations of pregnancy (ETOP), stillbirths, complications in previous
180 pregnancies and familial predisposition to congenital anomalies, developmental disorders, and motor
181 disorders.

182
183 4) The category *Use of medicines, folic acid / pregnancy vitamins and other health products* is
184 divided into the use of medication, folic acid and/or pregnancy vitamins, and other health products,
185 including details on administration route, amount of the exposure ('dose') and exact timing of

186 initiation and duration of exposure during pregnancy. Exposure to medicines and health products in
 187 the 6 months before the start of the current pregnancy is also questioned, along with paternal
 188 medication use in the 3 months before conception and maternal medication use in the first eight
 189 weeks postpartum.

190
 191 5) The category *Substance use* includes variables questioning maternal exposure to alcohol,
 192 tobacco (i.e., smoking), cannabis, and other illicit substances. Besides, substance use in the proximity
 193 of the woman (‘passive exposure’) is covered as well, for example, by questioning about ‘in-house’
 194 smoking by persons living together with the mother.

195
 196 6) In the category *Pregnancy outcomes*, the addressed variables vary depending on the
 197 pregnancy outcome of the current pregnancy, i.e., the occurrence of a live birth, miscarriage, ectopic
 198 pregnancy, elective termination of pregnancy or stillbirth. In case of a live birth, additional questions
 199 about the delivery and potential postpartum complications are included.

200
 201 7) The category *Neonatal outcomes* covers the health parameters of the infant, including the
 202 identification of congenital anomalies and the occurrence of neonatal complications, but also the
 203 feeding of the infant.

204

205 **Table 1.** Overview of the overarching BELpREG categories and variables, according to their
 206 occurrence in one of the four types of survey instruments

BELpREG categories and variables	Pregnancy Enrolment Questionnaire	Pregnancy Follow-up Questionnaire	First Postpartum Questionnaire	Second Postpartum Questionnaire
Category 1: Sociodemographics	x			
Category 2: Information on the current pregnancy and health status				
Pregnancy status		x		
EDD ¹ and/or current gestational age	x	x		
Singleton / multiple pregnancy	x			
Pregnancy preparation and planning	x			
Health status pregnant woman	x			
Health status and biological father (if applicable)	x			
Pregnancy complications and hospital admissions	x	x	x	
Prenatal screening for congenital anomalies				
Edinburgh Depression Scale (EDS-10)	x			x
Category 3: Maternal-obstetric history				
Gravidity and Parity	x			
History of miscarriages, ETOPs ² and stillbirths	x			
History of fertility treatments	x			
Complication(s) previous pregnancy/pregnancies	x			
Familial congenital anomalies	x			
Familial developmental disorders	x			
Familial motor disorders	x			
Category 4: Use of medicines, folic acid / pregnancy vitamins and other health products				
Medication use during pregnancy	x	x	x	
Use of folic acid or pregnancy vitamins prior to / in pregnancy	x	x	x	

Health products use during pregnancy	x	x	x	
Use of medicines and other health products in the 6 months before conception	x			
Paternal medication use in the 3 months before conception	x			
Maternal medication use in the 8 weeks after delivery			x	x
Category 5: Substance use				
Maternal smoking	x	x	x	x
Maternal alcohol use	x	x	x	x
Cannabis and other illicit drug use by the woman	x	x	x	x
Substance use in the proximity of the woman	x			
Category 6: Pregnancy outcomes			x	
Outcomes in case of 'live born child'				
Single or multiple birth			x	
Delivery (e.g., onset of labor, type of delivery...)			x	
Postpartum complications			x	x
Outcomes if miscarriage, ectopic pregnancy, ETOP ² or stillbirth			x	
Category 7: Neonatal outcomes				
Biometry at birth (e.g., weight, length, head circumference)			x	x
Sex			x	
Apgar score			x	
Congenital anomalies			x	x
Neonatal Abstinence symptoms			x	x
Neonatal medium or intensive care admission			x	x
Breastfeeding of the infant (e.g., breastfeeding, formula,...)			x	x
Neonatal complications			x	x
Medication use by the infant			x	x


207 3.2 Longitudinal Framework for Data Collection

208 Determining the interval of successive questionnaires and the timing and frequency of addressing
 209 specific variables were key elements in the design of the BELpREG longitudinal framework.
 210 Following careful consideration, an interval of 4 weeks between two successive questionnaires was
 211 chosen, with data collection until 8 weeks postpartum, except in case of consent withdrawal or early
 212 pregnancy interruption.

213 Four different survey instruments, each with specific data variables, were constructed: i.e., A) the
 214 Pregnancy Enrolment Questionnaire; B) the Pregnancy Follow-up Questionnaire; C) the First
 215 Postpartum Questionnaire; and D) the Second Postpartum Questionnaire. Table 1 gives an overview
 216 of the categories and variables questioned in each of the different questionnaires.

217 Figure 2 provides a general overview of the BELpREG longitudinal framework, i.e., from enrolment
 218 to study execution and termination of participation. More practical details about the framework are
 219 provided in the following paragraph.

220 **Figure 2.** Overview of the BELpREG longitudinal framework, from enrolment to study execution



221

222 To start data-collection, self-enrolment by pregnant persons is required, by using the link on the
223 BELpREG website (www.belpreg.be) or scanning the QR code on BELpREG flyers. Enrolment is
224 possible at any time during pregnancy, but participants will be encouraged to start as soon as possible
225 in pregnancy. Once a pregnant person has enrolled, a new record ID is automatically generated in the
226 BELpREG database, allowing longitudinal data collection on individual level. Upon completion of
227 the digital consent procedure (see 3.3.1) and appropriateness check of the eligibility criteria (i.e.,
228 being pregnant, ≥ 18 years and receiving healthcare in Belgium), the Pregnancy Enrolment
229 Questionnaire immediately starts. This is the most comprehensive questionnaire to be completed. It
230 may take 20-30 minutes or even more, depending on gestational age at enrolment, gravidity and the
231 number of medicines used during the current pregnancy so far. Completion of the *Sociodemographic*
232 *characteristics* in the Pregnancy Enrolment Questionnaire triggers the scheduling of the subsequent
233 e-mail invitations for the Pregnancy Follow-up Questionnaires. These Pregnancy Follow-up
234 Questionnaires are generally expected to require less time to be completed, i.e., $\pm 5-10$ minutes,
235 depending on the number of medicines, vitamins and health products used. The Pregnancy Follow-up
236 Questionnaires mainly focus on medication and health products' use since the latest completed
237 questionnaire (i.e., ideally, four weeks before), but also contain questions on pregnancy
238 complications and maternal substance use (see Table 1 1). If a Pregnancy Follow-up Questionnaire is
239 not completed after two weeks, a reminder is automatically sent via e-mail. The invitations for
240 subsequent Pregnancy Follow-up Questionnaires are sent out, irrespective of whether the previous
241 questionnaire(s) were completed, but with a maximum of 10 invitations per person. Once a
242 participant indicates that the pregnancy has ended, the First Postpartum Questionnaire immediately
243 appears. In case a miscarriage, stillbirth, ectopic pregnancy, or pregnancy termination is registered,
244 participants do not receive additional questionnaires for this pregnancy anymore. They can register
245 themselves again in the event of a new pregnancy. Only if a live birth is registered in the First
246 Postpartum Questionnaire, the Second Postpartum Questionnaire is sent out four weeks later. In case
247 of a live born twins, the questions related to Neonatal outcomes are automatically duplicated in both
248 Postpartum Questionnaires. A Second Postpartum Questionnaire is only sent out if the First
249 Postpartum Questionnaire was completed in the first 28 days after birth.

250 Finally, the data entry forms in the category *Use of medicines, folic acid / pregnancy vitamins and*
251 *other health products* have a longitudinal 'memory function'. This means that, if daily used
252 medicines or health products were registered, the names of these products as well as details related to

253 its use are automatically shown in the next questionnaire(s). This functionality gives participants the
254 opportunity to quickly and easily indicate if they still use the product in a similar way or not, and
255 hence, to save time because of this easy registration.

256 **3.3 Infrastructure of the BELpREG Registration System**

257 The BELpREG registration system was built using Research Electronic Data Capture (REDCap)
258 software (Harris et al., 2009; Harris et al., 2019; Van Bulck et al., 2022). REDCap is a secure, web-
259 based, software platform, used to collect, manage, and store longitudinal research data. The
260 BELpREG REDCap system, database and back-up system are hosted on an institutional server
261 separated from other institutional REDCap projects, providing an additional layer of security. The
262 BELpREG REDCap system adheres to high-level data security standards and requires a multi-factor
263 authentication procedure for investigators to get access. Only pre-authorized users with fixed roles
264 (*users rights*) have access to the BELpREG REDCap management tool and database. Access to
265 REDCap records is automatically logged, and changes to recorded data are stored in *independent*
266 *audit trails*. In BELpREG, REDCap's security measures for identifiable data apply, i.e., *identifier*
267 *tags* are attached to variables collecting identifiers, ensuring that only pseudonymized data will be
268 extracted out of the database.

269 To fit the REDCap software to the specific needs of the BELpREG project, the following features
270 have been created: 1) digital consent procedure (*eConsent*) (see 3.3.1), 2) linkage of BELpREG
271 survey instruments with databases of medications and health products (see 3.3.2); and 3) linkage of
272 BELpREG survey instruments with external databases (see 3.3.3), to facilitate both data entry,
273 coding, and analysis, and to enhance user satisfaction.

274 **3.3.1 eConsent Procedure**

275 As personal and health data are processed in the BELpREG project, the General Data Protection
276 Regulation (GDPR) applies for each processing activity. Given the sensitive nature of the collected
277 data, along with our ambitions with respect to data pooling as part of (international) collaborative
278 projects, obtaining informed consent from participants prior to enrolment was necessary. However,
279 as pregnant persons should be able to enrol without physical/in-person contact with the BELpREG
280 researchers, the availability of a digital, 'remote' consent ('eConsent') was vital. Besides, according
281 to applicable legislation in Belgium on research involving human subjects, authentication of
282 participants was needed as part of the BELpREG consent procedure and required a simple solution.

283 The following eConsent procedure was developed using REDCap software and is currently in place
284 (see Supplementary Material 2). First, potential participants watch an instructive video, available on
285 the BELpREG website (www.belpreg.be), providing information on the objectives and course of the
286 project, inclusion criteria, risks and benefits, consent withdrawal and confidential treatment of the
287 collected data; this replaces the 'in-person' provision of study information as part of a regular
288 informed consent process. In case of questions, the researchers can easily be contacted via the
289 website, email, or phone. After watching the video, participants are redirected to the REDCap
290 environment. Once individuals confirm that they watched the video and want to sign the consent
291 form, an automatic e-mail is sent out containing a One-Time-Password (OTP), which should be used,
292 as authentication procedure, to sign the form 'remotely'. Once it is completed, a copy of the form is
293 stored by the researchers and sent to the participant, who can immediately start with the Pregnancy
294 Enrolment Questionnaire. This eConsent procedure, and the overall BELpREG research project, have
295 been approved by the local Ethics Committee Research UZ/KU Leuven (S66464).

296 **3.3.2 Linked Databases of Medicines and Health Products**

297 The survey instrument on *Use of medicines, folic acid / pregnancy vitamins and other health*
298 *products* includes linkages with both the official Belgian medication database (i.e., “Source
299 Authentique des Médicaments” or SAM) and the Medipim database (i.e., a database containing
300 recent pictures of the packages of commercially available medicines and health products in Belgium).
301 When participants enter the name of a medicine, vitamin, or other health product in a BELpREG
302 questionnaire field, a structured and relevant dropdown list (based on both databases) appears that
303 facilitates the selection of the right product. The linked databases allow data collection on
304 medication, vitamin, and health products’ use in a structured, reliable, and user-friendly way. At the
305 same time, by using underlying structured data fields, the technical details of the registered medicines
306 and products, such as, for example, the Anatomical Therapeutic Chemical classification (ATC) code
307 and the route of administration, are automatically extracted from the linked databases and imported
308 into the BELpREG database.

309 **3.3.3 Other Linked Databases**

310 In addition to the structured data entry of medicines, vitamins, and health products, other BELpREG
311 variables also have underlying databases generating structured dropdown lists in their response field.
312 This is the case for the registration of 1) country of residence and nationality (i.e., linked to the
313 NATO database); 2) city of residence (i.e., linked to the database of the national post service in
314 Belgium); 3) name of the hospital where the delivery took place (i.e., linked to the database of the
315 National Institute for Health and Disability Insurance); and 4) the names of individual HCPs
316 following-up BELpREG participants during pregnancy and in the postpartum period (i.e., also linked
317 to a database of the latter national institute). Furthermore, to register (chronic) disorders or
318 indications of medications, participants can choose from a list of frequently reported
319 indications/disorders. This list was developed based on literature and clinical experience with
320 pregnant women and will grow over time (with up to five updates per year) based on experiences
321 obtained by the registrations of BELpREG participants using this list. In the back-end of the system,
322 the indications/disorders are linked to their respective ICD-11 (International Classification of
323 Diseases 11th Revision, n.d.) and MedDRA code (Medical Dictionary for Regulatory Activities,
324 n.d.), facilitating data processing, analysis, and reporting, and data pooling.

325

326 4 Discussion

327 4.1 Development and Design of the BELpREG Registration System

328 In this paper, we described the development and design of the BELpREG registration system,
329 enabling the prospective collection of ‘real-world’, observational data on perinatal medication use
330 and mother-infant outcomes in Belgium. After almost two years of constructing the system, we
331 succeeded in delivering the BELpREG infrastructure, including data variables, longitudinal
332 framework, digital consent and linkage with medication and other databases. Given the current lack
333 of routine data collection and pharmacoepidemiologic research on perinatal medication use in
334 Belgium, BELpREG can be considered a unique registration system/initiative that merits attention
335 from researchers, MAHs and policy makers in Belgium and beyond.

336 In the next paragraphs, we will discuss in detail the value of the BELpREG variables (see 4.1.1),
337 longitudinal framework and infrastructure (see 4.1.2) and recruitment of pregnant persons (see 4.1.3)
338 and will elaborate on potential strengths and limitations of the system.

339 4.1.1 The BELpREG Variables

340 The current tools used for the registration of medication exposure in pregnancy and mother-infant
341 outcomes, as part of international research initiatives on perinatal medication safety, often differ in
342 terms of exposure and outcome variables, including clinical definitions and coding standards (Thurin
343 et al., 2022). Such registration variety clearly complicates data pooling across countries, necessitating
344 additional standardization and alignment procedures with the inherent risk of considerable loss of
345 data and/or granularity. Data pooling is, however, very important in this field to enlarge the sample
346 size and power to detect significant associations, especially when studying rare outcomes such as
347 (specific types of) congenital malformations (Gelperin et al., 2017).

348 Relying on relevant documents on medication safety in pregnancy research, such as the IMI
349 ConcePTION Core Data Elements (ConcePTION, n.d.), we pursued and eventually delivered a list of
350 variables that are in line with those applied in other international data collection initiatives,
351 facilitating data pooling in the future. Contextualization to the Belgian setting was, however,
352 considered appropriate, to maximize the feasibility and likelihood of obtaining complete and reliable
353 data for all variables and to ensure user involvement and satisfaction. Contextualization was done
354 with input from an interdisciplinary panel consisting of experts from the main professions involved in
355 perinatal care. Despite the large number of variables, which may be cumbersome for participants, the
356 integration of a broad set of potential confounders for associations between medication use and
357 pregnancy outcomes is a strength of the BELpREG system. In fact, observational studies using health
358 utilisation data typically lack information on many confounders, entailing limitations in terms of the
359 validity of the conclusions (Huybrechts et al., 2019; Panchaud et al., 2022). With respect to the
360 feeding status of the infant, breastfeeding or receiving breast milk will be asked, which is considered
361 an important but often ignored source of medication exposure, a mitigator of adverse effects or a
362 relevant covariate in pharmacoepidemiologic research on the long-term effects of medication use in
363 pregnancy (Jordan et al., 2022).

364 4.1.2 The BELpREG Longitudinal Framework and Technical Infrastructure

365 As the ambition is to use BELpREG data for longitudinal research, the BELpREG system needed to
366 consist of online questionnaires which are sent and (ideally) completed by pregnant persons at
367 multiple time points during and after pregnancy. We opted for a fixed interval of four weeks, lasting
368 – at least for now – until eight weeks postpartum. By choosing this time interval, we tried to find the

369 right balance between registration fatigue among participants and recall bias for the self-reported
370 registration of medication and/or health products used in the previous period (van Gelder et al.,
371 2018). Upon enrolment, BELpREG participants are prospectively followed-up, i.e., they register
372 exposure data throughout pregnancy without knowing the pregnancy outcome yet. Collecting data in
373 a prospective way is an important strength in observational research, potentially decreasing the risk
374 of bias (Schaefer et al., 2008). Yet, in the Pregnancy Enrolment Questionnaire, we ask what
375 medicines/health products were used from the start of pregnancy until then. In case of late enrolment
376 during pregnancy (i.e., at more advanced gestational age), the risk of recall bias could be very
377 relevant. In any case, in all our communication, we advise and encourage individuals to enrol as early
378 as possible during pregnancy, although enrolment is possible at any gestational age.

379 To support participants in registering their medicines and health products, a linkage with databases of
380 medicines and health products available in Belgium was built, including pictures of the drug
381 packages (see 3.3.2). At user level, these linkages may improve the user friendliness of the system
382 (i.e., by facilitating the registration of their products from a dropdown list). At system level, the
383 linkages with medication and other types of databases, for example related to nationality or zip-code,
384 may have positive effects in terms of correctness/quality of the collected data (i.e., by
385 selecting/recognizing the correct product by means of its picture) and ease of further data processing
386 (i.e., by automatically importing relevant parameters, such as ATC code, in the BELpREG database).

387 The retained variables, linked databases and longitudinal framework were built into REDCap
388 software, which is an internationally recognized research tool for data collection and management
389 (Harris et al., 2009; Harris et al., 2019; Van Bulck et al., 2022), facilitating data collection initiatives
390 in other settings or countries in the future by relying on the BELpREG infrastructure.

391 When defining the BELpREG design, the perspectives of MAHs towards medication safety
392 monitoring and pharmacovigilance during pregnancy have been considered (Sillis et al., 2022),
393 thereby maximizing the added value of BELpREG for MAHs and facilitating future collaborations
394 by means of contract research with, for example, the aim to update the pregnancy statements in the
395 product labels (Roque Pereira et al., 2022).

396 Nevertheless, when using the BELpREG data for descriptive/analytical pharmacoepidemiologic
397 purposes, it should be noted that the reliability of the conclusions depends on the quality of the self-
398 reported data. Hence, assessing the correctness of the collected data by means of a validation study is
399 warranted and has already been initiated (see 4.2).

400 **4.1.3 Recruitment of Pregnant Individuals**

401 The success of ‘citizen science’ initiatives such as BELpREG depends on the level of involvement by
402 pregnant participants. Likewise, its success also lies in collaborating with other data collection
403 initiatives abroad, especially as Belgium is a small country with ‘only’ 120 000 pregnant women per
404 year (Statbel, 2023). Therefore, difficulties can be expected to obtain enough exposed women, solely
405 based on data collection in our country, to draw firm conclusions on associations. Data pooling will
406 be key, also for timely signal detection. Nevertheless, capturing every single piece of data is ethically
407 appropriate and must be pursued.

408 To reach pregnant persons, also those who are not using (chronic) medicines, applying diverse
409 recruitment methods is vital (Goldstein et al., 2021). Therefore, to date, pregnant persons are
410 informed about BELpREG both in-person (direct, by HCPs) and online (indirect). First, details about
411 BELpREG are being shared with different types of HCPs involved in perinatal care (i.e.,

412 obstetricians, midwives, general practitioners, pharmacists...), with support from their professional
413 organizations and regional care organizations. The embeddedness of BELpREG in the local
414 healthcare context for pregnant persons may be a critical aspect for its successful uptake by potential
415 users (Sillis et al., 2022). Sustainable partnerships between the research team and HCPs, prenatal care
416 organizations and hospitals has earlier been shown as a core strategy for successful recruitment
417 (Goldstein et al., 2021), and are currently being set-up in within BELpREG. Second, indirect
418 recruitment strategies are being used by means of our website, social media (Facebook, Instagram),
419 and printed/digital posters and flyers. As poor public awareness of research among different groups
420 within the population is a large barrier for participation in research (Goldstein et al., 2021), social
421 media can be an effective method to reach a broader audience, independent from efforts by HCPs. In
422 fact, the population of pregnant women often uses social media to search for information (Sinclair et
423 al., 2018). In addition, high internet penetration rates exist among women of childbearing age in
424 Belgium (Statbel, 2022). Previous research has shown the advantages of recruiting pregnant women
425 through social media, including advertisement via these channels (van Gelder et al., 2019). Although
426 social media seem a logical recruitment channel for BELpREG, its effectiveness should be further
427 explored, including the effect of directly approaching the target population via (advertising using)
428 social media (Sarker et al., 2017).

429 As study enrolment in BELpREG occurs without physical contact with the researchers, the ability to
430 provide remote informed consent is paramount. Therefore, in BELpREG, a user-friendly and GDPR
431 compliant eConsent framework was specifically developed according to the applicable legislation in
432 Belgium (see 3.3.1). The use of an eConsent in REDCap has previously been shown to be feasible
433 and easy-to-use by pregnant women (Phillippi et al., 2018). In the future, the BELpREG eConsent
434 framework could serve as an instrument or starting point for similar research purposes in other
435 populations and/or settings.

436 **4.2 Future Perspectives of BELpREG**

437 As part of the development stage, the BELpREG infrastructure was extensively tested 'in-house' on
438 functionality and technical performance by different persons and by using different scenarios. In
439 November 2022, public data collection has officially started. However, as the next step, we have
440 planned to closely follow-up and explore the ongoing data collection in 'real-life' and the preliminary
441 data. Such iterative process of testing, followed by possible system modifications, will result in a
442 robust, patient-friendly, and fit-for-purpose research instrument, ready for large-scale implementation
443 in Belgium and beyond. The assessment will focus on 1) the completeness of the collected data, both
444 within (i.e., missing variables) and across questionnaires (i.e., loss to follow-up); 2) the 'reach' or
445 representativeness of the BELpREG sample (as research using online questionnaires typically only
446 reaches a select group of the population (Vorstenbosch et al., 2019; van Gelder et al., 2020; Stegherr
447 et al., 2022)); 3) users' experiences and challenges with data entry (by means of a mixed-methods
448 approach); 4) experiences of HCPs with informing and motivating pregnant individuals to participate
449 in BELpREG.

450 In addition to the feasibility assessment, we will undertake a validation study to evaluate the quality
451 of the self-reported data. Patients may probably be best placed to record their medication use (van
452 Gelder et al., 2018), however, it remains unclear to what extent they are able to correctly register
453 pregnancy and neonatal outcomes (e.g., type and description of congenital anomalies). Therefore, the
454 validity of self-registered health data will be assessed by comparing with the data available in
455 medical/obstetric records (only for participants who gave consent to contact their HCPs). In case the
456 validation study shows that these variables can indeed be reliably registered by patients, this will

457 avoid an additional registration burden for HCPs. Overall, it should be further explored to what
458 extent HCPs would be able to register data in BELpREG themselves, for example for patients with
459 low health literacy or impaired internet access.

460 Another important future perspective relates to the exploration for long-term follow-up of children
461 born after prenatal exposure to medicines. To date, the BELpREG design only includes maximum
462 two questionnaires in the first eight weeks postpartum, addressing neonatal health outcomes.
463 However, some exposures may result in adverse neurodevelopmental outcomes in offspring, which
464 only become visible months or years after birth (Liu et al., 2017; Bromley and Bluett-Duncan, 2021).
465 We have the ambition to extend our postpartum questionnaires for long-term follow-up purposes, and
466 therefore look expectantly at the ongoing LIFETIME project (i.e., Long-term Investigation Following
467 Exposure To Individual Medicines in utero) (ConcePTION, n.d.). As a first step, BELpREG
468 participants are being asked about their willingness to complete self-reported surveys at the age of
469 developmental milestones (Hjorth et al., 2019).

470 Finally, translating the BELpREG questionnaires into other (national) languages (e.g., French,
471 English) is also an intended goal, which we hope to achieve in the (near) future.

472 **5 Conclusions**

473 Due to the current lack of routine data collection and pharmacoepidemiologic research on medication
474 safety in pregnancy in Belgium, the BELpREG registration system was developed. As a ‘citizen
475 science’ project, the BELpREG system enables the prospective and longitudinal collection of
476 comprehensive, real-world data on perinatal medication use and mother-infant outcomes. Online
477 questionnaires will be completed by pregnant persons every four weeks during pregnancy and in the
478 first eight weeks postpartum.

479 The variables were compiled using relevant documents and through an expert panel consultation and
480 are structured in seven categories. A digital, ‘remote’ informed consent and linkage to medication
481 databases, with images of drug packages and underlying structured data fields, are built into the
482 system, which uses REDCap as software. Data collection has officially started in November 2022.

483 Based on its rigorous and fully digital design, BELpREG holds the potential to be a successful,
484 sustainable, and collaborative research tool, enabling perinatal pharmacoepidemiologic research in
485 Belgium and beyond. Researchers, MAHs and policy makers are invited to contact the researchers to
486 explore future collaborations and data pooling, with the aim to reduce the current knowledge gap in
487 this field and to provide more evidence on medication safety in pregnancy to patients and HCPs.

488 **6 Conflict of Interest**

489 The authors declare that the research was conducted in the absence of any commercial or financial
490 relationships that could be construed as a potential conflict of interest.

491 **7 Supplementary Material**

492 The following supporting information can be downloaded: Supplementary Table1: Detailed overview
493 of the BELpREG variables, per category; Supplementary Figure 2: Schematic overview of the
494 eConsent procedure.

495

496 **8 Author Contributions**

497 Conceptualization, L.S., V.F. and M.C.; methodology, L.S., V.F., K.A., A.B., M.D.V., T.H., A.S.,
498 K.V.C., J.Y.V. and M.C.; software, L.S. and M.C.; validation, L.S., V.F. and M.C.; formal analysis,
499 L.S. and M.C.; investigation, L.S. and M.C.; resources, V.F., M.C. and L.S.; data curation, L.S.;
500 writing-original draft preparation, L.S. and M.C.; writing-review and editing, V.F., K.A., A.B.,
501 M.D.V., T.H., A.S., K.V.C., and J.Y.V.; supervision, V.F. and M.C.; project administration, L.S. and
502 M.C.; funding acquisition, V.F., M.C. and L.S.. All authors have read and agreed to the published
503 version of the manuscript.

504 **9 Funding**

505 The development of BELpREG was funded by a KU Leuven internal fund (C3/020/095). The
506 research activities of Laure Sillis are funded by the Research Foundation Flanders (FWO)
507 (1S35823N). The research activities of Michael Ceulemans are supported by the Department of
508 Pharmaceutical and Pharmacological Sciences and the Faculty of Pharmaceutical Sciences of the KU
509 Leuven.

510 **10 Acknowledgments**

511 The authors would like to thank the following persons for their input and help through the
512 development of BELpREG: Hilde De Tollenaere and Peter Van Rompaey (Clinical Trial Center,
513 University Hospitals Leuven), Eugène Van Puijenbroek (Lareb, NL), Saskia Vorstenbosch (NL),
514 Carlijn Litjens (NL), Ellen Ederveen (Lareb, NL), Judith Hendriks (Lareb, NL), Jonathan Luke
515 Richardson (UKTIS, UK), Rebecca Bromley and Matthew Bluett-Duncan (University of Manchester,
516 UK), Liesbet Van Bulck (KU Leuven), Alexis Puvrez (KU Leuven) and Gert Goos (ICT Service, KU
517 Leuven). The authors are also grateful to the BELpREG partners Digile (IT support - An Crepel,
518 Karel De Loof and Davy Hollevoet), Medipim (providing pictures of medicinal products),
519 Allen&Overy (legal advice) and Isabelle Geeraerts (graphical design). Finally, the authors thank all
520 colleagues and women who have contributed to the in-house testing of the system.

521 **12 Data Availability Statement**

522 Not applicable.

523 **11 Note from the authors**

524 The list of used REDCap features is not exhaustive. The mentioned features of REDCap used in the
525 BELpREG project are a choice of the authors. Complete information about REDCap features can be
526 found here: <https://projectredcap.org/>.

527 **12 References**

- 528 Adam, M.P., Polifka, J.E., and Friedman, J.M. (2011). Evolving knowledge of the teratogenicity of
529 medications in human pregnancy. *American Journal of Medical Genetics Part C: Seminars in*
530 *Medical Genetics* 157(3), 175-182. doi: 10.1002/ajmg.c.30313.
- 531 Benevent, J., Hurault-Delarue, C., Araujo, M., Montastruc, J.L., Lacroix, I., and Damase-Michel, C.
532 (2019). POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine
533 Exposure. *Drug Saf* 42(1), 45-54. doi: 10.1007/s40264-018-0712-9.

- 534 Bergink, V., Kooistra, L., Lambregtse-van den Berg, M.P., Wijnen, H., Bunevicius, R., van Baar, A.,
535 et al. (2011). Validation of the Edinburgh Depression Scale during pregnancy. *J Psychosom*
536 *Res* 70(4), 385-389. doi: 10.1016/j.jpsychores.2010.07.008.
- 537 Bromley, R.L., and Bluett-Duncan, M. (2021). Neurodevelopment Following Exposure to Antiseizure
538 Medications in Utero: A Review. *Curr Neuropharmacol* 19(11), 1825-1834. doi:
539 10.2174/1570159x19666210716111814.
- 540 Ceulemans, M., Fortuin, M., Van Calsteren, K., Allegaert, K., and Foulon, V. (2020). Prevalence and
541 characteristics of pregnancy- and lactation-related calls to the National Poison Centre in
542 Belgium: A retrospective analysis of calls from 2012 to 2017. *Journal of Evaluation in Clinical*
543 *Practice* 26(3), 911-917. doi: 10.1111/jep.13228.
- 544 Ceulemans, M., Foulon, V., Panchaud, A., Winterfeld, U., Pomar, L., Lambelet, V., et al. (2022a).
545 Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-
546 19 Pandemic: A Cross-Sectional Study in Five European Countries. *International Journal of*
547 *Environmental Research and Public Health* 19(3), 1389. doi: 10.3390/ijerph19031389.
- 548 Ceulemans, M., Van Calsteren, K., Allegaert, K., and Foulon, V. (2022b). Information Needs and
549 Counseling Preferences among Potential Users of the Future Teratology Information Service
550 in Belgium: A Cross-Sectional Study Involving the Public and Healthcare Professionals.
551 *International Journal of Environmental Research and Public Health* 19(14), 8605. doi:
552 10.3390/ijerph19148605.
- 553 Chambers, C.D., Johnson, D.L., Xu, R., Luo, Y., Lopez-Jimenez, J., Adam, M.P., et al. (2019). Birth
554 outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study.
555 *PLOS ONE* 14(10), e0223603. doi: 10.1371/journal.pone.0223603.
- 556 ConcePTION. (n.d.). <https://www.imi-conception.eu/> [Accessed February 14, 2023].
- 557 Cox, J.L., Holden, J.M., and Sagovsky, R. (1987). Detection of Postnatal Depression. *British Journal*
558 *of Psychiatry* 150(6), 782-786. doi: 10.1192/bjp.150.6.782.
- 559 Dandjinou, M., Sheehy, O., and Bérard, A. (2019). Antidepressant use during pregnancy and the risk
560 of gestational diabetes mellitus: a nested case-control study. *BMJ Open* 9(9), e025908. doi:
561 10.1136/bmjopen-2018-025908.
- 562 Dao, K., Shechtman, S., Diav-Citrin, O., George, N., Richardson, J.L., Rollason, V., et al. (2022).
563 Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy: A
564 Comparative ENTIS Cohort Study. *Journal of Clinical Psychopharmacology*,
565 10.1097/JCP.0000000000001630. doi: 10.1097/jcp.0000000000001630.
- 566 EMA (2019). "GVP Product- or Population-Specific Considerations III: Pregnant and breastfeeding
567 women (EMA/653036/2019) - Draft for public consultation".).
- 568 Gelperin, K., Hammad, H., Leishear, K., Bird, S.T., Taylor, L., Hampp, C., et al. (2017). A systematic
569 review of pregnancy exposure registries: examination of protocol-specified pregnancy
570 outcomes, target sample size, and comparator selection. *Pharmacoepidemiology and Drug*
571 *Safety* 26(2), 208-214. doi: 10.1002/pds.4150.
- 572 Gerbier, E., Favre, G., Tauqeer, F., Winterfeld, U., Stojanov, M., Oliver, A., et al. (2022). Self-
573 Reported Medication Use among Pregnant and Postpartum Women during the Third Wave of
574 the COVID-19 Pandemic: A European Multinational Cross-Sectional Study. *International*
575 *Journal of Environmental Research and Public Health* 19(9), 5335. doi:
576 10.3390/ijerph19095335.
- 577 Gerbier, E., Graber, S.M., Rauch, M., Marxer, C.A., Meier, C.R., Baud, D., et al. (2021). Use of drugs
578 to treat symptoms and acute conditions during pregnancy in outpatient care in Switzerland
579 between 2014 and 2018: analysis of Swiss healthcare claims data. *Swiss Med Wkly* 151,
580 w30048. doi: 10.4414/smw.2021.w30048.
- 581 Goldstein, E., Bakhireva, L.N., Nervik, K., Hagen, S., Turnquist, A., Zgierska, A.E., et al. (2021).
582 Recruitment and retention of pregnant women in prospective birth cohort studies: A scoping

- 583 review and content analysis of the literature. *Neurotoxicology and Teratology* 85, 106974. doi:
584 <https://doi.org/10.1016/j.ntt.2021.106974>.
- 585 Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O'Neal, L., et al. (2019). The REDCap
586 consortium: Building an international community of software platform partners. *Journal of*
587 *Biomedical Informatics* 95, 103208. doi: 10.1016/j.jbi.2019.103208.
- 588 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009). Research
589 electronic data capture (REDCap)—A metadata-driven methodology and workflow process for
590 providing translational research informatics support. *Journal of Biomedical Informatics* 42(2),
591 377-381. doi: 10.1016/j.jbi.2008.08.010.
- 592 Hernandez-Diaz, S., and Oberg, A.S. (2015). Are Epidemiological Approaches Suitable to Study
593 Risk/Preventive Factors for Human Birth Defects? *Current Epidemiology Reports* 2(1), 31-36.
594 doi: 10.1007/s40471-015-0037-5.
- 595 Hernandez-Diaz, S., Smith, C.R., Shen, A., Mittendorf, R., Hauser, W.A., Yerby, M., et al. (2012).
596 Comparative safety of antiepileptic drugs during pregnancy. *Neurology* 78(21), 1692-1699. doi:
597 10.1212/wnl.0b013e3182574f39.
- 598 Hjorth, S., Bromley, R., Ystrom, E., Lupattelli, A., Spigset, O., and Nordeng, H. (2019). Use and
599 validity of child neurodevelopment outcome measures in studies on prenatal exposure to
600 psychotropic and analgesic medications – A systematic review. *PLOS ONE* 14(7), e0219778.
601 doi: 10.1371/journal.pone.0219778.
- 602 Huybrechts, K.F., Bateman, B.T., and Hernández-Díaz, S. (2019). Use of real-world evidence from
603 healthcare utilization data to evaluate drug safety during pregnancy. *Pharmacoepidemiology*
604 *and Drug Safety* 28(7), 906-922. doi: 10.1002/pds.4789.
- 605 Huybrechts, K.F., Bateman, B.T., Zhu, Y., Straub, L., Mogun, H., Kim, S.C., et al. (2021).
606 Hydroxychloroquine early in pregnancy and risk of birth defects. *American Journal of*
607 *Obstetrics and Gynecology* 224(3), 290.e291-290.e222. doi: 10.1016/j.ajog.2020.09.007.
- 608 International Classification of Diseases 11th Revision (ICD-11). (n.d.). <https://icd.who.int/en>
609 [Accessed February 14, 2023].
- 610 Jordan, S., Bromley, R., Damase-Michel, C., Given, J., Komninou, S., Loane, M., et al. (2022).
611 Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the
612 information desert. *International Breastfeeding Journal* 17(1). doi: 10.1186/s13006-022-
613 00494-5.
- 614 Lacroix, I., Hurault, C., Sarramon, M.F., Guitard, C., Berrebi, A., Grau, M., et al. (2009). Prescription
615 of drugs during pregnancy: a study using EFEMERIS, the new French database. *European*
616 *Journal of Clinical Pharmacology* 65(8), 839-846. doi: 10.1007/s00228-009-0647-2.
- 617 Larcin, L., Lona, M., Karakaya, G., Van Espen, A., Damase-Michel, C., and Kirakoya-
618 Samadoulougou, F. (2021). Using administrative healthcare database records to study trends in
619 reimbursed medication dispensed during pregnancy in Belgium from 2003 to 2017.
620 *Pharmacoepidemiol Drug Saf.* doi: 10.1002/pds.5299.
- 621 Liu, X., Agerbo, E., Ingstrup, K.G., Musliner, K., Meltzer-Brody, S., Bergink, V., et al. (2017).
622 Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide
623 register based cohort study. *BMJ*, j3668. doi: 10.1136/bmj.j3668.
- 624 Lupattelli, A., Spigset, O., Twigg, M.J., Zagorodnikova, K., Mårdby, A.C., Moretti, M.E., et al. (2014).
625 Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open*
626 4(2), e004365. doi: 10.1136/bmjopen-2013-004365.
- 627 Magnus, P., Irgens, L.M., Haug, K., Nystad, W., Skjærven, R., and Stoltenberg, C. (2006). Cohort
628 profile: The Norwegian Mother and Child Cohort Study (MoBa). *International Journal of*
629 *Epidemiology* 35(5), 1146-1150. doi: 10.1093/ije/dyl170.
- 630 Medical Dictionary for Regulatory Activities (MedDRA). (n.d.). <https://www.meddra.org/> [Accessed
631 February 14, 2023].

- 632 Moseholm, E., Katzenstein, T.L., Pedersen, G., Johansen, I.S., Wienecke, L.S., Storgaard, M., et al.
633 (2022). Use of antiretroviral therapy in pregnancy and association with birth outcome among
634 women living with HIV in Denmark: A nationwide, population-based cohort study. *HIV*
635 *Medicine* 23(9), 1007-1018. doi: 10.1111/hiv.13304.
- 636 Nörby, U., Noël-Cuppers, B., Hristoskova, S., Desai, M., Härmark, L., Steel, M., et al. (2021). Online
637 information discrepancies regarding safety of medicine use during pregnancy and lactation: an
638 IMI ConcePTION study. *Expert Opinion on Drug Safety* 20(9), 1117-1124. doi:
639 10.1080/14740338.2021.1935865.
- 640 Panchaud, A., Cleary, B., Weber-Schoendorfer, C., Shechtman, S., Cassina, M., Diav-Citrin, O., et al.
641 (2022). The risk of questioning the safety of drugs considered safe in pregnancy at the era of
642 big data: the everlasting case of doxylamine. *J Clin Epidemiol* 152, 125-126. doi:
643 10.1016/j.jclinepi.2022.10.007.
- 644 Pauliat, E., Onken, M., Weber-Schoendorfer, C., Rousson, V., Addor, M.-C., Baud, D., et al. (2021).
645 Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS
646 study. *Multiple Sclerosis Journal* 27(3), 475-478. doi: 10.1177/1352458520929628.
- 647 Phillippi, J.C., Doersam, J.K., Neal, J.L., and Roumie, C.L. (2018). Electronic Informed Consent to
648 Facilitate Recruitment of Pregnant Women Into Research. *Journal of Obstetric, Gynecologic*
649 *& Neonatal Nursing* 47(4), 529-534. doi: 10.1016/j.jogn.2018.04.134.
- 650 Roque Pereira, L., Durán, C.E., Layton, D., Poulentzas, G., Lalagkas, P.-N., Kontogiorgis, C., et al.
651 (2022). A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register
652 and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A
653 Contribution from the ConcePTION Project. *Drug Safety* 45(4), 333-344. doi: 10.1007/s40264-
654 022-01154-7.
- 655 Sarker, A., Chandrashekar, P., Magge, A., Cai, H., Klein, A., and Gonzalez, G. (2017). Discovering
656 Cohorts of Pregnant Women From Social Media for Safety Surveillance and Analysis. *Journal*
657 *of Medical Internet Research* 19(10), e361. doi: 10.2196/jmir.8164.
- 658 Scaffidi, J., Mol, B., and Keelan, J. (2017). The pregnant women as a drug orphan: a global survey of
659 registered clinical trials of pharmacological interventions in pregnancy. *BJOG: An*
660 *International Journal of Obstetrics & Gynaecology* 124(1), 132-140. doi: 10.1111/1471-
661 0528.14151.
- 662 Schaefer, C., Ornoy, A., Clementi, M., Meister, R., and Weber-Schoendorfer, C. (2008). Using
663 observational cohort data for studying drug effects on pregnancy outcome--methodological
664 considerations. *Reprod Toxicol* 26(1), 36-41. doi: 10.1016/j.reprotox.2008.05.064.
- 665 Shields, K.E., and Lyerly, A.D. (2013). Exclusion of pregnant women from industry-sponsored clinical
666 trials. *Obstet Gynecol* 122(5), 1077-1081. doi: 10.1097/AOG.0b013e3182a9ca67.
- 667 Sillis, L., Foulon, V., Verbakel, J.Y., and Ceulemans, M. (2022). Experiences and Perspectives of
668 Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A
669 Pan-European Qualitative Analysis. *International Journal of Environmental Research and*
670 *Public Health* 19(7), 4248. doi: 10.3390/ijerph19074248.
- 671 Sinclair, M., Lagan, B.M., Dolk, H., and McCullough, J.E.M. (2018). An assessment of pregnant
672 women's knowledge and use of the Internet for medication safety information and purchase.
673 *Journal of Advanced Nursing* 74(1), 137-147. doi: 10.1111/jan.13387.
- 674 Statbel. (2022). ICT use in households in Belgium. [https://statbel.fgov.be/nl/themas/huishoudens/ict-
675 gebruik-huishoudens](https://statbel.fgov.be/nl/themas/huishoudens/ict-gebruik-huishoudens) [Accessed February 14, 2023].
- 676 Statbel. (2023). Births and Fertility in Belgium. [https://statbel.fgov.be/nl/themas/bevolking/geboorten-
677 en-vruchtbaarheid](https://statbel.fgov.be/nl/themas/bevolking/geboorten-en-vruchtbaarheid) [Accessed February 14, 2023].
- 678 Stegherr, R., Beck, E., Hultsch, S., Schaefer, C., and Dathe, K. (2022). Can non-responding mask or
679 mimic drug effects on pregnancy outcome? Evaluation of case characteristics based on the
680 national Embryotox cohort. *Reproductive Toxicology*. doi: 10.1016/j.reprotox.2022.05.013.

- 681 Thurin, N.H., Pajouheshnia, R., Roberto, G., Dodd, C., Hyeraci, G., Bartolini, C., et al. (2022). From
682 Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and
683 Communication of Medication Safety During Pregnancy and Breastfeeding. *Clinical*
684 *Pharmacology & Therapeutics* 111(1), 321-331. doi: 10.1002/cpt.2476.
- 685 Van Bulck, L., Wampers, M., and Moons, P. (2022). Research Electronic Data Capture (REDCap):
686 tackling data collection, management, storage, and privacy challenges. *European Journal of*
687 *Cardiovascular Nursing* 21(1), 85-91. doi: 10.1093/eurjcn/zvab104.
- 688 van Gelder, M.M.H.J., Merkus, P.J.F.M., Van Drongelen, J., Swarts, J.W., Van De Belt, T.H., and
689 Roeleveld, N. (2020). The PRIDE Study: Evaluation of online methods of data collection.
690 *Paediatric and Perinatal Epidemiology* 34(5), 484-494. doi: 10.1111/ppe.12618.
- 691 van Gelder, M.M.H.J., Rog, A., Bredie, S.J.H., Kievit, W., Nordeng, H., and Belt, T.H. (2019). Social
692 media monitoring on the perceived safety of medication use during pregnancy: A case study
693 from the Netherlands. *British Journal of Clinical Pharmacology* 85(11), 2580-2590. doi:
694 10.1111/bcp.14083.
- 695 van Gelder, M.M.H.J., Van De Belt, T.H., Engelen, L.J.L.P.G., Hooijer, R., Bredie, S.J.H., and
696 Roeleveld, N. (2019). Google AdWords and Facebook Ads for Recruitment of Pregnant
697 Women into a Prospective Cohort Study With Long-Term Follow-Up. *Maternal and Child*
698 *Health Journal* 23(10), 1285-1291. doi: 10.1007/s10995-019-02797-2.
- 699 van Gelder, M.M.H.J., Vorstenbosch, S., Te Winkel, B., van Puijenbroek, E.P., and Roeleveld, N.
700 (2018). Using Web-Based Questionnaires to Assess Medication Use During Pregnancy: A
701 Validation Study in 2 Prospectively Enrolled Cohorts. *Am J Epidemiol* 187(2), 326-336. doi:
702 10.1093/aje/kwx239.
- 703 Vorstenbosch, S., Te Winkel, B., van Gelder, M.M.H.J., Kant, A., Roeleveld, N., and van Puijenbroek,
704 E. (2019). Aim and Design of pREGnant, the Dutch Pregnancy Drug Register. *Drug Saf* 42(1),
705 1-12. doi: 10.1007/s40264-018-0722-7.
- 706 Zhao, Y., Du, G., Luan, X., Yang, H., Zhang, Q., Zhang, Z., et al. (2022). Registered Clinical Trials
707 Comprising Pregnant Women in China: A Cross-Sectional Study. *Frontiers in Pharmacology*
708 13. doi: 10.3389/fphar.2022.850080.